MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-11-30, NRIX had $137,030K increase in cash & cash equivalents over the period. -$263,467K in free cash flow.

Cash Flow Overview

Change in Cash
$137,030K
Free Cash flow
-$263,467K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-11-30
Net loss
-264,457
Depreciation and amortization
8,740
Stock-based compensation
37,965
Net accretion of discount on marketable securities
10,322
Loss on disposal of property and equipment
-89
Amortization of operating lease right-of-use assets
10,116
Other
0
Prepaid expenses and other assets
6,229
Accounts payable
-630
Deferred revenue
-36,980
Operating lease liabilities
-5,067
Accrued expenses and other current liabilities
17,310
Net cash used in operating activities
-249,465
Purchases of marketable securities
455,688
Maturities of marketable securities
617,543
Purchases of property and equipment
14,002
Net cash provided by (used in) investing activities
147,853
Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs
234,762
Proceeds from exercise of stock options and pre-funded warrants
1,651
Proceeds from issuance of common stock under employee stock purchase plan
2,229
Proceeds from issuances of common stock in 'at the market' financing, net of issuance costs
0
Repurchase of unvested early exercised stock options
0
Net cash provided by financing activities
238,642
Net increase (decrease) in cash, cash equivalents and restricted cash
137,030
Cash and cash equivalents at beginning of period
110,898
Cash and cash equivalents at end of period
247,928
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. (NRIX)